RAF1 and fibrosarcoma: Sorafenib is a multi-target TKI, acting through suppression of multiple pathways such as rapid accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinases (ERK) and inhibition of inhibition of VEGFR 2/3 and PDGFR.